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ABSTRACT
The European Paediatric Pulmonary Vascular Disease
(PVD) Network is a registered, non-profit organisation
that strives to define and develop effective, innovative
diagnostic methods and treatment options in all forms of
paediatric pulmonary hypertensive vascular disease,
including specific forms such as pulmonary arterial
hypertension (PAH)-congenital heart disease, pulmonary
hypertension (PH) associated with bronchopulmonary
dysplasia, persistent PH of the newborn, and related
cardiac dysfunction.
Methods The writing group members conducted
searches of the PubMed/MEDLINE bibliographic database
(1990–2015) and held five face-to-face meetings with
votings. Clinical trials, guidelines, and reviews limited to
paediatric data were searched using the terms
‘pulmonary hypertension’ and 5–10 other keywords, as
outlined in the other nine articles of this special issue.
Class of recommendation (COR) and level of evidence
(LOE) were assigned based on European Society of
Cardiology/American Heart Association definitions and
on paediatric data only, or on adult studies that included
>10% children.
Results A total of 9 original consensus articles with
graded recommendations (COR/LOE) were developed,
and are summarised here. The topics included diagnosis/
monitoring, genetics/biomarker, cardiac catheterisation,
echocardiography, cardiac magnetic resonance/chest CT,
associated forms of PH, intensive care unit/ventricular
assist device/lung transplantation, and treatment of
paediatric PAH.
Conclusions The multipaper expert consensus statement
of the European Paediatric PVD Network provides a
specific, comprehensive, detailed but practical framework
for the optimal clinical care of children with PH.
Pulmonary hypertensive vascular disease (PHVD) is a
fatal disease characterised by pulmonary vascular
remodelling, leading to elevated pulmonary
arterial pressure, right ventricular dysfunction, left
ventricular compression and consequently heart
failure.1–6 Despite significant advances in pulmonary
arterial hypertension (PAH)-targeted therapies,
survival of children and adults with idiopathic PAH
and other forms of group 1 pulmonary hypertension
(PH), such as persistent PAH after repair of congeni-
tal heart disease (CHD), remains poor.7–12 Morbidity
and mortality of paediatric PH represent substantial
and growing healthcare burden:12–15 From 1997 to
2012, shifts in case mix toward paediatric PH not
associated with CHD, non-cardiac procedures and
care in urban teaching hospitals have been noted in a
recent retrospective study in the USA.15 Based on a
separate analysis of the period 2000–2009, the
number of PH-related hospitalizations of children is
increasing, and the overall mortality for PH-related
hospitalizations is greater than that for hospitaliza-
tions not associated with PH (5.7% vs 0.4%; odds
ratio: 16.22 (95% CI 14.8% to 17.8%), p<0.001).16
Nevertheless, PH-associated mortality has been
decreasing over the recent years in children16 17 and
adults9 10 (box 1).
Objectives of the expert consensus statement
of the European Paediatric Pulmonary Vascular
Disease (PVD) Network
We were seeking to develop a framework that
better defines the course of paediatric PH, identifies
current gaps in our knowledge and provides a con-
sensus statement with practical recommendation on
how to best manage paediatric PH in diverse set-
tings, acknowledging that most recommendations
will have level of evidence (LOE) B or C. The 10
documents, including this executive summary, do
not comprehensively review the pathobiology and
clinical findings of paediatric PH, but rather
contain practical recommendations for healthcare
providers treating children and adolescents with
different forms of PH.
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The objectives of this multipaper consensus statement were
(1) to discuss the most recent classifications of PH: World
Symposium, Nice, 2013; progressive post-haemorrhagic ven-
tricular dilatation (PPHVD) pulmonary vascular resistance index
Panama 2011; European Society of Cardiology (ESC)/European
Respiratory Society (ERS), 2015; (2) to summarise clinical study
results and their limitations, (3) to provide graded, evidence-
and expert-based recommendations for the diagnosis and
treatment of infants, children and adolescents with PH (includ-
ing CHD/Eisenmenger syndrome), according to the grading
system provided by American Heart Association (AHA) and
ESC, (4) to address features specific to PH forms in childhood,
(5) to define the multiple gaps in our knowledge on paediatric
PH, (6) make suggestions on future trial design and (7) to
discuss emerging PH therapies (safety and efficacy).
METHODOLOGY
The European Paediatric PVD Network
The European Paediatric PVD Network is a registered non-
profit organisation that is independent of any medical–scientific
society and industry. The network strives to define and develop
effective, innovative diagnostic methods and treatment options
in all forms of paediatric PHVD, including specific forms such
as PAH–-CHD, PH associated with bronchopulmonary dysplasia
(BPD), persistent PH of the newborn (PPHN) and related
cardiac dysfunction. In order to achieve these objectives, an
interdisciplinary writing group (WG) was assembled to develop
a multipaper expert consensus statement that is being published
in this special issue of Heart.
Composition of the PVD Network’s WG ‘Expert Consensus
Statement on the Diagnosis and Treatment of Paediatric
Pulmonary Hypertension’
The WG members were recruited from Austria, Germany,
Finland, France and the UK. The WG consists of 23 paediatri-
cians (with subspecialty expertise and board certifications in
paediatric cardiology, critical care and/or neonatology), a clinical
physiologist and a thoracic transplant surgeon. The WG started
within the German Paediatric PVD Network, a newly founded
WG of the German Society of Paediatric Cardiology (DGPK) in
Box 1 Rationale for an expert consensus statement on
paediatric pulmonary hypertension
▸ Diagnostic and therapeutic strategies in children with
pulmonary hypertension (PH) are markedly influenced by
unique features of the pulmonary circulation in childhood
(developmental biology) and certain paediatric diseases that
are commonly associated with PH.
▸ A new World Symposium on Pulmonary Hypertension
(WSPH) classification18 was published in December 2013
and slightly modified in the new 2015 European Society of
Cardiology European Respiratory Society guidelines on the
diagnosis and treatment of PH—a document that mainly
focuses on clinical care in adults.
▸ Yet, we felt that comprehensive, detailed but practical
recommendations addressing the specifics of PH and
pulmonary vascular disease in children are lacking.
▸ Recent randomized controlled trials on mono or combination
PH therapy have enrolled a substantial number of children,
or—more recently—have been exclusively designed to study
PH in children (eg, STARTS-1, -2).
▸ Analyses of several paediatric patient registries (TOPP,
REVEAL, COMPERA KIDS) and basic science and clinical
advances have led to multiple high-impact publications in
the past 10 years.
▸ The unique features of paediatric PH were—for the first time
—recognized at the 2013 WSPH in Nice, resulting in a brief
10-page document on paediatric PH.19 In addition, the first
specific paediatric pulmonary hypertensive vascular disease
classification (Pulmonary Vascular Research Institute,
Panama) published in 201120 is currently undergoing
revisions and modifications, as practicing PH doctors aim to
apply the detailed paediatric-specific classification. Hence,
this multipaper expert consensus statement on the paediatric
PH by our network is timely indeed.
Table 2 Levels of evidence
LOE A Data derived from multiple randomized clinical trials or
meta-analyses.
LOE B Data derived from a single randomized clinical trial or large
non-randomized studies.
LOE C Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
LOE, as currently proposed by the European Society of Cardiology and the American
Heart Association. The colour coding was used throughout the executive summary
and all individual subtopic manuscripts of the ‘Expert Consensus Statements on the
Diagnosis and Treatment of Paediatric Pulmonary Hypertension—The European
Paediatric Pulmonary Vascular Disease Network’.
LOE, level of evidence.
Table 1 Classes of recommendations
Classes of
recommendations Definition Suggested wording to use
Class I Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Is recommended/is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion. May be considered
Class III Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may
be harmful.
Is not recommended
Classes of recommendations, as currently proposed by the European Society of Cardiology and the American Heart Association. The colour coding was used throughout the executive
summary and all individual subtopic manuscripts of the ‘Expert Consensus Statements on the Diagnosis and Treatment of Paediatric Pulmonary Hypertension—The European Paediatric
Pulmonary Vascular Disease Network’.
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2013, and then quickly evolved into the multinational European
Paediatric PVD Network that now publishes the expert consen-
sus statement. The majority of the 24 authors of the PVD net-
work’s WG are also members of the WG of ‘PH and heart
failure’ of the ‘Association for European Paediatric and
Congenital Cardiology’ (AEPC). Georg Hansmann is chair and
Christian Apitz is co-chair of the according WG of the
European Paediatric PVD Network.
Special features of this expert consensus statement—the
multipaper approach leading to recommendations for the
practicing physician and specialised PH doctor
▸ Conventional consensus statements or guidelines published
by scientific societies tend to be >40-page documents
attempting to cover all aspects of an often very heteroge-
neous disease, and thus may—at times—become too
unwieldy to fully address the needs of the practicing health-
care providers and their patients, immediate relatives and
insurance companies. WGs are usually large and—due to the
time-consuming voting, writing and editing processes—very
relevant original publications of the preceding 12–18 months
often cannot be included in such a large document before it
is published.
▸ We followed a novel approach and created small taskforces
within an interdisciplinary international multiexpert WG, to
develop nine individual papers by clinical topic plus this
executive summary and grouped the manuscripts in a special
issue entitled ‘paediatric pulmonary hypertension’. All 10
papers include graded recommendations according to the
grading system provided by the ESC and the AHA. All arti-
cles underwent a rigorous peer review process (see below).
▸ Within the multipaper concept, we divided the topics as they
relate to the ‘syndrome paediatric PH’ by the clinical
Table 3 Recommendations on diagnosis, monitoring and outpatient care in children with suspected or confirmed PH/PPHVD21
Recommendations COR LOE
Children with suspected or confirmed PH/PPHVD should be referred to, comprehensively evaluated and treated in multidisciplinary, specialised paediatric
centres.
I C
The initial evaluation should include a comprehensive medical history, thorough physical examination, assignment to a functional class and formal
assessment of cardiac function (ECG and echocardiogram). This should be followed by further diagnostic testing to delineate the PH aetiology—ideally
prior to the initiation of therapy.
I B
A CXR is recommended at baseline with acceptable risk/ radiation exposure. I B
Regular CXRs at follow-up are not indicated, unless there is a clinical reason. III B
Serial echocardiograms and ECGs are recommended every 3–6 months. In unstable or symptomatic patients or those who undergo therapeutic changes,
more frequent echocardiograms may be indicated.
I B
Further imaging is recommended to exclude underlying parenchymal lung disease, pulmonary veno-occlusive disease, CTEPH and anatomical
obstructions, which may be beyond what can be diagnosed by routine transthoracic echocardiography.
I C
If CTEPH is suspected, and a definite diagnosis is still pending despite exhaustion of other imaging modalities (cardiac catheter, chest CT), a ventilation–
perfusion scan can be useful for selected patients.
IIa C
If no underlying cause of the PH is evident, an abdominal ultrasound is indicated to rule out liver cirrhosis and/or portal hypertension. I C
A sleep study (polysomnography) should be performed in patients with PH at risk for sleep-disordered breathing, especially patients with Trisomy 21,
other syndromes or patients with significant daytime sleepiness.
I B
In patients with PH who are not particularly at risk for sleep-disordered breathing but have an inadequate response to PAH-targeted pharmacotherapy, a
sleep study is recommended and can provide additional information.
I B
Serial CPET (treadmill, bicycle) and the 6MWT are recommended to assess and monitor exercise tolerance, gauge prognosis and for surveillance of
therapy in children with PH of an appropriate age.
I B
Pulse oximetry during CPET/6MWT is helpful to allow shunt detection, especially in patients with PAH–CHD. IIa C
Blood gas analysis in paediatric patients with PH can be useful at rest, at ventilatory threshold and at maximal exercise during CPET. If available, analysis
should include haemoglobin and lactate.
IIa C
A basic lung function test (ie, body plethysmography) should be performed at the time of diagnosis, to rule out any coexisting airway disease/lung





▸ mPAP ≥25 mm Hg in children >3 months of age at sea level
PAH
▸ mPAP ≥25 mm Hg
▸ PCWP <15 mm Hg
▸ PVR index >3 WU×m2
Idiopathic Pulmonary Arterial Hypertension (PAH)
▸ PAH with no underlying disease known to be associated
with PAH
Hereditary PAH
▸ PAH with no underlying disease but with positive family
history or positive genetic testing
Pulmonary hypertensive vascular disease
For biventricular circulations:
▸ mPAP ≥25 mm Hg and PVR index >3 WU×m2
For circulations with cavopulmonary anastomosis (eg, Fontan
physiology):
▸ mean TPG >6 mm Hg (calculate mPAP minus mLAP or
PCWP) or PVR index >3 WU×m2
▸ Detailed haemodynamic definitions of PH (eg, precapillary vs
postcapillary PH, value of the diastolic transpulmonary
pressure gradient) by the European Paediatric Pulmonary
Vascular Disease Network are presented in ref. 23.
▸ mPAP, mean pulmonary artery pressure; mLAP, mean left
atrial pressure; PAH, pulmonary artery hypertension; PCWP,
pulmonary capillary wedge pressure (syn. PAWP, pulmonary
artery wedge pressure); PVR, pulmonary vascular resistance;
and TPG, transpulmonary pressure gradient; WU, Wood
units.
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scenario they usually occur in real life, that is, general recom-
mendations on diagnosis/monitoring;21 specific diagnostics
tools, that is, biomarker/genetics;22 cardiac catheterisation;23
echocardiography;24 and cardiac magnetic resonance/CT.25
▸ Moreover, we addressed two disease-specific, complex and
common patient groups separately: (1) PH/PHVD associated
with CHD, including recommendations that are relevant for
both children and adolescents/adults with PAH-CHD,26 and
(2) PPHN and BPD/chronic lung disease in infancy.27
▸ Finally, detailed recommendations on therapy are given in
two documents: (1) treatment of acute PH in the intensive
care unit, including ventricular assist device (VAD)/extracor-
poreal membrane oxygenation and lung transplantation
(LuTx),28 and (2) comprehensive recommendations on mid-
Table 4 Recommendations on the use of genetic testing and biomarkers in children with PH.22
Recommendations COR LOE
Genetic counselling is recommended for families with children suffering from severe genetic disorder. This includes children with IPAH or HPAH. I B
Families of patients with syndromes associated with PAH should be educated on the symptoms of PAH and recommended to seek clinical evaluation if
the child should develop symptoms of PAH.
I C
It is recommended to screen asymptomatic PAH mutation carriers, also children, with serial echocardiograms, and potentially other non-invasive studies I C
Genetic testing for PAH-associated genes such as ACVRL1, BMPR2, CAV1, ENG and KCNK3 can be useful for children with PAH of unknown cause to
allow definition of aetiology, estimation of prognosis and identification of family members at risk, and to inform family planning.
IIa C
Genetic testing of first-degree relatives of an index patient with PAH and a known disease-causing mutation can be useful for risk stratification and
rationalising surveillance.
IIa C
Genetic testing for mutations in EIF2AK4 gene should be considered for children with suspicion of PVOD to allow for definition of aetiology and
identification of family members at risk, and to inform family planning.
IIa C
HPAH patient’s family members who develop new cardio-respiratory symptoms should be evaluated immediately for PAH I C
Comprehensive NGS panels targeting all known genetics in PAH can be considered to maximise diagnostic efficacy and increase cost-effectiveness in
genetic diagnostics
IIb C
Genetic testing for PAH-associated genes can be considered for patients with CHD and ‘out of proportion’ PAH (eg, PAH with small atrial shunt). IIb C
Measurement of natriuretic peptides BNP or NT-proBNP is recommended to evaluate disease severity, progression and treatment response in patients
with PH.
I B
It is uncertain whether analysis of uric acid levels can be used to evaluate disease severity IIb C
Analysis of circulating endothelial cells can be useful to stratify operative risk, evaluate for progression of disease and/or response to therapy in children
with PAH
IIa B
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 22.
ACVRL1 (ALK1), activin-like kinase-type 1; BMPR2, bone morphogenetic protein receptor 2; BNP, brain natriuretic peptide; CAV1, caveolin 1; CHD, congenital heart disease; COR,
class of recommendation; EIF2AK4, eukaryotic translation initiation factor 2-α kinase 4; ENG, endoglin; HPAH, hereditary pulmonary arterial hypertension; IPAH, idiopathic
pulmonary arterial hypertension; KCNK3, potassium channel subfamily K, member 3; LOE, level of evidence; NGS, next-generation sequencing; NT-proBNP, N-terminal fragment of
pro-brain natriuretic peptide; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease.
Table 3 Continued
Recommendations COR LOE
In children with end-stage disease, timely referral to and discussion with a transplant centre should be sought, if lung transplantation represents a
considerable option for the individual patient.
I C
For children with PH/PPHVD undergoing surgery or other interventions requiring sedation or general anaesthesia, consultation with cardiac anaesthesia
and the PH service, and appropriate postprocedure monitoring is required.
I C
Good communication between teams, awareness of the severity of the disease, timely preparation (including ‘standby’ of inhaled nitric oxide) and
conscious anaesthetic strategies maintaining an adequate systemic vascular resistance and adequate preload, are recommended to reduce morbidity as
well as fatal events
I C
Female adolescents with PH/PPHVD should undergo timely counselling regarding the significant maternal and foetal pregnancy risks and options for
secure contraception.
I B
Paediatric patients with PH in the high-risk category should not participate in competitive sports. I C
It is recommended that children with mild-to-moderate PH/PPHVD should engage in light-to-moderate aerobic activity, but be allowed to self-limit their
activities as required.
I C
Children with PH should avoid strenuous and isometric exercise, as well as dehydration. I C
It is recommended that children with PH should only fly on commercial aeroplanes in a stable and compensated condition. I C
Children with PH should undergo all recommended routine vaccinations to prevent any deteriorations due to avoidable infections. I C
RSV (<2 years of age), pneumococcal and influenza vaccinations should be administered in paediatric patients with PH if no contraindications exist. I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref.21
Recommendations on PH diagnostics and monitoring, specifically in neonatal chronic lung disease and persistent PH of the newborn,27 and PAH associated with congenital heart
disease,,26 are outlined in separate articles of the PVD network.
6MWT, six-minute walk test; COR, class of recommendation; CPET, cardiopulmonary exercise testing; CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest X-ray;
HR-chest CT, high resolution chest CT; LOE, level of evidence; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PPHVD, paediatric pulmonary hypertensive
vascular disease; PVD, Pulmonary Vascular Disease; RSV, respiratory syncytial virus.
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Table 5 Recommendations on haemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with
pulmonary vascular disease23
Recommendations COR LOE
Cardiac catheterisation is indicated in all paediatric patients with PH to confirm diagnosis, evaluate the severity and when PH-specific drug therapy is
considered.
I C
Initial cardiac catheterisation should include right as well as left heart catheterisation to establish the diagnosis (not only RHC), if there is no
contraindication.
I C
Cardiac catheterisation may be omitted in acutely presenting, critically ill patients requiring immediate initiation of therapy I B
Cardiac catheterisation for the diagnosis of PAH should include AVT, unless there is a reasonable contraindication, such as PH associated with left heart
disease (PH Group II)
I C
AVT to assess prognosis and indication for specific PH therapy: The haemodynamic change that defines a positive response to AVT in PH without shunt
(Qp:Qs=1:1) for children should be considered as a >20% fall in mean PAP and PVRi/SVRi ratio without a decrease in cardiac output
IIa C
Haemodynamic indicators of PH severity are PVRi/SVRi ratio and PVRi, rather than percent fall in mean pulmonary artery pressure during AVT. Severe PH
with high PVRi/SVRi ratio and high PVRi requires advanced and/or combination therapy.
IIa C
AVT to assess operability of APAH-CHD: The haemodynamic change that defines a positive response to AVT in PH with shunt (Qp:Qs >1.5:1)
for children should be considered as a >20% fall in PVRi and PVRi/SVRi with respective final values<6 iWU and <0.3.
IIa C
Cardiac catheterisation and acute vasoreactivity testing should be performed in experienced paediatric heart centres, able to manage potential
complications such as PH crisis, potentially requiring extracorporeal membrane oxygenation (depending on disease severity).
I C
The patient’s level of consciousness during cardiac catheterisation should be consistent in subsequent invasive assessments. I C
The preferred mode to perform cardiac catheterisation in a patient PH/PPHVD who is spontaneously breathing, either awake or moderately sedated. I C
Vasoreactivity testing should be performed using nitric oxide as vasodilator. I C
Vasoreactivity testing with the initial combination of nitric oxide and oxygen is reasonable and shortens the AVT study. IIa C
The use of calcium channel blocker, intravenous epoprostenol or intravenous adenosine in acute vasoreactivity testing is not recommended in children




Repeat cardiac catheterisation should be considered in case of clinical deterioration for assessment of treatment effect, detection of early disease
progression, listing for lung transplant in children with PH/PPHVD/PAH.
IIa C
Intervals for repeat catheterisations should be based on clinical judgement but include worsening clinical course, significant change in pharmacotherapy
(eg, drug class), or failure to improve during treatment
I C
It may be reasonable to have a stable patient with PH/PPHVD on combination therapy (>one medication) undergoing cardiac catheterisation every
12–24 months
IIb C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association, and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 23.
AVT, acute vasoreactivity testing; CHD, congenital heart disease; COR, class of recommendation; LOE, level of evidence; PAP, pulmonary artery pressure; PAH, pulmonary arterial
hypertension; PH, pulmonary hypertension; PPHVD, paediatric pulmonary hypertensive vascular disease; PVRi, indexed pulmonary vascular resistance; RHC, right heart
catheterisation; SVRi, indexed systemic vascular resistance.
Table 6 Recommendation on transthoracic echocardiography (TTE) in paediatric pulmonary hypertension24
Recommendations COR LOE
1. Following the initial diagnostic evaluation for PH, TTE should be performed at 3–6 month intervals or earlier when the clinical condition or medication
changes
I C
2. A TTE study of a child with a suspected PH should include the assessment of the following variables:
2.1. Estimation of the systolic PAP, by estimating RVSP through the measurement of the velocity of the TR jet by CW Doppler I B
2.2. Estimation of mean PAP and end-diastolic PAP through CW Doppler of pulmonary regurgitation jet IIa C
2.3. RV longitudinal systolic function (tricuspid annular plane systolic excursion) I B
2.4. RV strain and strain rate measurements IIb C
2.5. RV volumes by three-dimensional echocardiography IIb C
2.6. RV systolic to diastolic duration ratio (CW Doppler, TR jet) IIb C
2.7. Tissue Doppler velocities (LV, septal, RV) IIa B
2.8. RV/LV diameter ratio IIa C
2.9. PA acceleration time (PAAT) IIb C
3. The presence of a PE by TTE indicates poorer survival in adults with PH. PE develops frequently in patients with PAH. Currently, no data on the
significance of PE in paediatric PH are available
IIb C
4. RA enlargement plus interatrial septal bowing from right to left shows poor RV compliance or increased mean RA pressure in adults. Currently, no data
on RA dilation in paediatric PH are available
IIb C
5. TTE is useful method to screen for increased PAP I B
6. TTE can neither establish the definite diagnosis of PH nor classify PH subgroups, and is not sufficient to initiate a targeted therapy I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology (ESC) and the American Heart Association (AHA), and were based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be
found in ref. 24. COR, class of recommendation; CW, continuous wave; EI, eccentricity index; LOE, level of evidence; LV, left ventricle; PAAT, pulmonary artery acceleration time;
PAP, pulmonary artery pressure; PE, pericardial effusion; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PR, pulmonary regurgitation; RA, right atrium; RV,
right ventricle; RVSP, right ventricular systolic pressure; S0, peak systolic velocity; SR, strain rate; TAPSE; Tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TTE,
transthoracic echocardiography.
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Table 7 Recommendations on the use of cardiac magnetic resonance and computed tomography in children with suspected or confirmed
PH/ PPHVD25
Recommendations COR LOE
cMRI without anaesthesia/sedation is recommended in children with suspected PH/PPHVD as part of the diagnostic evaluation and during follow-up to assess changes
in ventricular function and chamber dimensions.
I B
It is recommended that a cMRI study of a child with suspected PH/PPHVD should include the following modules. Cine cMRI for the assessment biventricular volume,
function and mass using a stack of axial or short axis slices covering the entire heart.
I B
A cMRI study of a child with suspected PH/PPHVD should include the following modules: Standard 2D flow (PCMRI) measurements at the MPA, RPA, LPA, AAO. I B
A cMRI study of a child with suspected PH/PPHVD may include the following modules: standard 2D flow (PCMRI) measurements at the pulmonary veins. IIb B
A cMRI study of a child with suspected PH/PPHVD may include the following modules: late gadolinium enhancement may be considered for the assessment of
presence and amount of myocardial fibrosis.
IIb C
It is uncertain whether a cMRI study of a child with suspected PH/PPHVD should include simultaneous invasive pressure measurements (cMRI guided cardiac
catheterisation) to calculate PVR (combined with pulmonary flow measurements) and/or to assess load-independent indices of ventricular function (combined with
ventricular flow measurements).
IIb C
A cMRI study of a child with suspected PH/PPHVD may include the following modules: gadolinium contrast-enhanced or non-contrast-enhanced angiography to assess
morphology and size of the pulmonary arteries, pulmonary arterial tree and quantify pulmonary perfusion (CE-MRI).
IIb C
It is uncertain whether a cMRI study of a child with suspected PH/PPHVD should include the following modules: Assessment of regional RV myocardial function by
cMRI tagging techniques.
IIb C
It is uncertain whether a CMR study of a child with suspected PH/PPHVD should include the following modules: Non-invasive estimation of RV afterload variables,
including RVP/PAP/PVR using different proposed cMRI techniques (interventricular septal position, flow measurements, pulmonary distensibility and elastance, RV–PA
coupling).
IIb C
High-resolution chest CT with angiography is recommended in the initial assessment of a child with suspected PH/PPHVD. I C
In case an obvious cause for PH/PPHVD, such as left-to-right cardiovascular shunt, a chest CT may be omitted. IIb C
High-resolution chest CT is indicated in every patient being evaluated for lung transplantation. I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association, and were based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 25.
2D, two-dimensional; AAO, ascending aorta; cMRI, cardiovascular MRI; CE-MRI, contrast-enhanced MRI; COR, class of recommendation; LOE, level of evidence; LPA, left pulmonary
artery; MPA, main pulmonary artery; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PCMRI, phase-contrast MRI; PPHVD, paediatric pulmonary hypertensive vascular
disease; PVR, pulmonary vascular resistance; RPA, right pulmonary artery; RVP, right ventricular pressure; RV–PA, right ventricular-pulmonary arterial.
Table 8 Recommendations on the evaluation and management of PH in children and adolescents with CHD (CHD–PAH, CHD–PPHVD)26
Recommendations COR LOE
Children/adolescents with clinically confirmed CHD should undergo specific transthoracic echocardiography (TTE) screening for PAH and/or ventricular dysfunction. TTE cannot
reliably distinguish between PAH with increased PVR (PPHVD) and without elevated PVR.
I C
In children and adolescents with PAH/PPHVD–CHD, a complete diagnostic work-up needs to be performed in order to determine whether PAH is associated or causally related to
concomitant CHD.
I C
Operability/catheter intervention: Surgery or interventional closure for CHD with simple post-tricuspid shunts (VSD, PDA) and significant left-to-right shunting should preferably be
performed within the first 6 months of life.
I C
Children with PAH–CHD and significant left-to-right shunting, congestive heart failure (pulmonary congestion), failure to thrive, and SpO2 >95% (lower extremities) can be
considered “operable” for shunt closure; however, perioperative PH crisis may occur.
IIa C
Children with PAH–CHD, significant left-to-right shunting and uncertainties regarding the PVR are recommended to undergo comprehensive right and left heart catheterisation
regardless of the patient’s age.
I C
Operability: Children with CHD and simple defects (VSD, PDA) beyond the typical date of surgery (see main text) or those with shunts and cyanosis should undergo comprehensive
right and left cardiac catheterisation (see CHD–PAH algorithm, figure 3).
I C
Children with PVRI <6 WU×m2 and a PVR/SVR ratio <0.3 in the absence of additional risk factors are eligible for standard management/surgery/percutaneous interventional device
closure
I C
Children with PVRI ≥6 WU×m2 and a PVR/SVR-ratio ≥0.3 have to be evaluated by acute vasodilative testing. I C
Operability in complex CHD has to be judged individually, considering age, size and type of lesions and associated syndromes. I C
In children/adolescents with single ventricle physiology, the haemodynamic threshold for operability pre Fontan surgery is probably a mean TPG <6 mm Hg IIa C
In clinically asymptomatic children/adolescents with single ventricle physiology and total cavopulmonary connection (Fontan), a PVRI <3 WU×m2 and mean TPG <6 mm Hg is
consistent with acceptable haemodynamics.
IIa C
Children/adolescents with total cavopulmonary connection (Fontan) signs of increased PVRI and/or low Qp and/or hepatic congestion should undergo complete diagnostic work-up,
including comprehensive cardiac catheterisation.
IIa C
In children/adolescents with total cavopulmonary connection (Fontan) and PHVD (TPG is ≥6 mm Hg), or those Fontan patients with symptoms irrespective of haemodynamics,
targeted PH therapies should be considered to improve exercise capacity.
IIa C
In inoperable children/adolescents with Eisenmenger syndrome, targeted pharmacotherapy as single drug or combination therapy (sequential, upfront) may be used, depending on
WHO functional class and symptoms.
IIa C
In inoperable children/adolescents with Eisenmenger syndrome, iron supplementation (by mouth, intravenously) may be administered if iron deficiency is present. IIb C
In inoperable children/adolescents with Eisenmenger syndrome, supplemental oxygen may be considered to reduce symptoms after careful examination (when PaO2<60 mm Hg). IIb C
In inoperable children with Eisenmenger syndrome and neurological symptoms (headaches, TIA, stroke), phlebotomy may be indicated in severe hyperviscosity syndrome (MCV
>80 fL).
IIb C
In inoperable children/adolescents with Eisenmenger syndrome, anticoagulation may be considered in the absence of haemoptysis. IIb C
In children/adolescents with PAH/PPHVD–CHD and left heart congestion either due to obstruction or secondary to myocardial dysfunction, it is recommended to perform full
haemodynamic evaluation by comprehensive right and left heart catheterisation.
I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 26.
CHD, congenital heart disease; COR, class of recommendation; LOE, level of evidence; MCV, mean corpuscular volume; PAH, pulmonary arterial hypertension; PDA, patent ductus
arteriosus; PH, pulmonary hypertension; PPHVD, paediatric pulmonary hypertensive vascular disease; PVR, pulmonary vascular resistance; PVRI, PVR index; Qp, pulmonary blood
flow; SVR, systemic vascular resistance; TIA, transient ischaemic attack; TPG, transpulmonary pressure gradient; TTE, transthoracic echocardiography; VSD, ventricular septal defect;
WU, Wood units.
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to long-term treatment of PH/PHVD in the inpatient and
outpatient setting, including pharmacotherapy, catheter inter-
ventions and surgery.29
Literature search, grading system of recommendations,
voting and review process
Literature search
Computerized searches of the PubMed/MEDLINE bibliographic
database were conducted for the time period 1990–2015.
Clinical trials, guidelines, and reviews limited to paediatric data
were searched using the terms ‘pulmonary hypertension’ and 5–
10 other keywords, as outlined in each of the 10 articles of this
special issue ’Expert Consensus Statement on the Diagnosis and
Treatment of Paediatric Pulmonary Hypertension’. The primary
focus of this manuscript is on group 1 PH, according to the
World Symposium on Pulmonary Hypertension (WSPH) classifi-
cation (Nice, 2013)18 that was recently slightly modified in the
‘ESC/ERS Guidelines on the Diagnosis and Treatment of
Pulmonary Hypertension’.30
Class of recommendation (COR), level of evidence (LOE)
The recommendations relate to the grading system for class of
recommendation (COR) and LOE currently proposed by the
ESC and the AHA (COR, table 1; LOE, table 2) and was
based on paediatric data only (paediatric studies, or adult
studies enrolling >10% children). The grading and voting
process is described further below. Within this executive
summary, only the recommendations listed in each table #1
of the 9 subtopic consensus statements are listed. A full list of
references can be found in the individual 9 subtopic articles.
Table 9 Recommendations for supportive measures and pharmacotherapy in PPHN and PH associated with BPD/nCLD27
Recommendations COR LOE
For the treatment of PH in the NICU, the term or preterm newborn infant should receive oxygen, ventilatory support and/or surfactant if needed to achieve
a preductal SpO2 between 91% and 95% when PH is suspected or established; lung hyperinflation and atelectasis, or lung collapse and intermittent
desaturations below 85%, or hyperoxia with preductal SpO2 above 97% should be avoided.
I A
In a newborn infant with acute PPHN in the first hours after birth, a pCO2 between 45–60 mm Hg and a target pH >7.25 with lactate <5mmol/L can be
considered as target values.
IIa B
The preterm and term neonate with severe PH (PPHN) and no post-tricuspid-unrestrictive shunt (e.g., no VSD) may receive PGE1 or PGE2 to maintain
ductal patency in right heart failure.
IIa B
Intratracheal surfactant can be considered for the preterm and term neonate with PPHN and pulmonary diffusion impairment (but without congenital
diaphragmatic hernia) to optimise ventilation, for example, newborn with meconium aspiration syndrome and PPHN.
IIa B
ECMO can currently not be recommended for the preterm infant <34 0/7 gestational weeks p.m. and/or <2000 g body weight, with severe PH. III B
The preterm infant with respiratory failure should not receive iNO for the prevention of BPD and associated PH, if not enrolled in a rigorously conducted
randomised clinical trial.
III A
iNO is indicated for treatment of PPHN in mechanically ventilated newborns to improve oxygenation and reduce the need for ECMO (a) if PaO2 is less
than 100 mm Hg (while receiving 100% oxygen), or (b) if the oxygenation index exceeds 25.
I A
Oral sildenafil should be considered for treatment of PPHN and PH in BPD, especially if iNO is not available. IIa B
Intravenous sildenafil may be considered for treatment of PH, including PPHN, in critically ill patients, especially in those with an unsatisfactory response
to iNO.
IIb B
In the neonate with PPHN or BPD, intravenous prostanoids through a dedicated central line or inhaled iloprost can be beneficial. IIa B
Treatment of severe PPHN may be extended to ECMO if other intensive care measures fail (http://www.elso.org). IIa B
In infants with severe BPD with or without PH, treatment with diuretics, that is, hydrochlorothiazide and spironolactone, can be considered as long as
cardiac preload is adequate.
IIa B
All infants with proven or suspected PH should receive close follow-up, including preductal/postductal SpO2 measurements, echocardiography (1/week
initially, then 1–2/month), and laboratory work-up depending on disease severity including NT-proBNP, BNP, troponin optional, guided by clinical
improvement or lack thereof.
I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 27.
BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; COR, class of recommendation; ECMO, extracorporeal membrane oxygenation; LOE, level of evidence; iNO, inhaled
nitric oxide; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; PGE, prostaglandin E; PPHN, persistent pulmonary hypertension of the newborn; PH, pulmonary
hypertension; VSD, ventricular septal defect.
Table 10 Recommendations on the therapy of acute PH in the paediatric intensive care unit28
Recommendations COR LOE
Oxygen should be given when transcutaneous oxygen saturation is <95% in children with PH and normal cardiac anatomy. I C
Intravenous prostanoids should be considered to treat children with severe PH. IIa B
iNO may be considered for treatment of postoperative PH in mechanically ventilated patients to improve oxygenation and reduce the risk of pulmonary
hypertensive crisis.
IIb B
Concomitant sildenafil should be administered to prevent rebound PH in patients who have signs of increased PAP on withdrawal of iNO, and require
restart of iNO despite preceding gradual weaning of iNO.
I B
Intravenous sildenafil may be considered for treatment of PH in critically ill patients, especially those with an unsatisfactory response to iNO. IIb B
Inhaled iloprost may be as effective as iNO in children with postoperative PH. IIb B
In children who develop signs of low cardiac output or profound pulmonary failure despite optimal medical therapy, extracorporeal life support may be
considered.
IIb C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of
Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 28.
COR, class of recommendation; ICU, intensive care unit; iNO, inhaled nitric oxide; LOE, level of evidence; PAP, pulmonary artery pressure; PH, pulmonary hypertension.
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Importantly, healthcare providers must adhere to the medica-
tion labelling and follow future drug recommendations/warn-
ings potentially published by the European Medicines Agency
(EMA) and the US Food and Drug Administration (FDA)
when transforming these recommendations into clinical
practice.
Voting process
The WG held five face-to-face meetings to discuss the individual
topics and conduct the voting on the wording of the recommen-
dations and the grading (COR, LOE) thereof (tables 1 and 2).
The according meetings were conducted on 28 January 2014 in
Bad Nauheim, Germany; on 28 July 2014 in Hannover,
Table 11 Recommendations on treatment of children with paediatric pulmonary hypertension29
Recommendations COR LOE
Oxygen therapy is reasonable in hypoxemic PH patients who consistently have oxygen saturations <92% or PaO2 <60 mm Hg IIa C
Inhalative oxygen can be particularly useful for patients with pulmonary hypertension and an element of parenchymal lung disease (eg,
bronchopulmonary dysplasia/nCLD).
IIa B
Inhalative oxygen can be useful for patients with intrapulmonary shunt and important for patients with PH while at altitude or during air travel. IIa C
Based on PAH and heart failure studies in adults, mineralcorticoid receptor blockade with spironolactone can be beneficial in patients with PAH by
improving RV and LV diastolic function, particularly in ‘heart failure with preserved ejection fraction’.
IIa C
Diuretic therapy may be considered for selected paediatric patients with pulmonary hypertension. IIb C
Diuretic therapy should be initiated cautiously since patients with PH/PPHVD are often pre-load dependent to maintain an optimal cardiac output. I C
The benefit of chronic anticoagulation (warfarin, phenprocoumon) in children with PAH is unclear (so far not studied in children). IIb C
Chronic anticoagulation can be useful in patients with progressive IPAH/HPAH (empirical goal INR 2.0–2.5), patients with chronic thromboembolic
pulmonary hypertension, patients with low cardiac output and those with hypercoagulable states.
IIa C
Indication for anticoagulation should be critically reviewed, especially in small children prone to haemorrhagic complications. In these cases, antiplatelet
therapy (eg, ASA) may be an alternative.
IIb C
Anticoagulation is potentially harmful in children with hereditary haemorrhagic telangiectasia or porto-pulmonary hypertension. III
harm
C
Before starting targeted PAH therapy for chronic PH/PPHVD, vasodilator responsiveness should be determined by cardiac catheterisation and anatomic
obstruction from pulmonary venous disease or from left-sided heart disease should be excluded.
I B
CCB: A trial of CCB monotherapy should be pursued only in those patients who have previously been shown to be acutely reactive to iNO±oxygen, that
is, those who have a positive acute vasoreactivity response (‘AVT responders’).
IIa C
For children with a negative acute vasoreactivity response or those with a failed or non-sustained response to CCBs, risk stratification should probably
determine additional targeted therapy.
IIa C
CCB are contraindicated in children who have not undergone AVT, non-responders to AVT, and those with right heart failure, that is, WHO functional




The majority of children with severe PAH are non-responsive to acute vasodilator testing to iNO±oxygen, and require ‘targeted’ therapy other than CCB. I C
In a child with mild-to-moderate chronic PH/PPHVD and lower risk (figure 1), initiation of oral goal-targeted therapy is recommended (figures 2 and 3),
regardless of a negative acute vasoreactivity response and should begin with either a PDE5-inhibitor or an endothelin receptor antagonist.
I B
Oral sildenafil can be useful in the setting of iNO therapy withdrawal in post-operative PH, or in the presence of PH related to chronic lung disease. IIa B
High-dose oral sildenafil treatment (defined in the STARTS-1/-2 RCT, and table 2), either as monotherapy or add-on drug, carries an unfavourable




Intravenous sildenafil can be advantageous in neonates with PPHN treated with or without iNO. IIa C
In severe (WHO functional class IV) and/or rapidly progressive PAH/PPHVD (diagnosed by cardiac catheterisation and non-invasive imaging), continuous
intravenous prostacyclin analogue therapy, that is, epoprostenol or treprostinil, should be started without delay (start with prostanoid monotherapy or
dual/triple combination therapy including prostacyclin analogues).
I C
Start of prostacyclin analogue therapy with intravenous treprostinil (COR IIa, C) or intravenous iloprost treprostinil (COR IIa, C) instead of epoprostenol
may be considered in certain circumstances, given the advantage of longer plasma half-life and greater stability/ease of application for both treprostinil
and iloprost.
IIa C
Early combination therapy with two oral PAH drugs in newly diagnosed (treatment naïve) children with PAH in WHO functional class II–III may be
considered
IIb C
Combination of intravenous (eg, epoprostenol, treprostinil intravenously) or subcutaneous prostacyclin analogues (treprostinil intravenously) with one or
two oral PAH-targeted drugs (eg, sildenafil, bosentan) may result in better long-term survival in PAH.
IIb C
iNO is mainly used in the intensive care unit setting and useful in patients with acute pulmonary vascular crisis and/or acute exacerbation of PH in the
setting of an underlying parenchymal lung disease and/or PPHN.
I B
Concomitant sildenafil should be administered to prevent rebound PH in patients who have signs of increased PAP on withdrawal of iNO, and require
restart of iNO despite preceding gradual weaning of iNO.
I B
Atrial septostomy can be considered in patients in functional class III and IV and recurrent syncope under combined medical therapy, and as palliative
bridge to transplant increasing the chance for survival while waiting for a donor organ.
IIb C
Based on a small series of children with end-stage PAH, a surgical anastomosis between the left pulmonary artery and the descending aorta (Potts shunt)
may be considered be a valuable alternative (destination therapy) or bridge to bilateral lung transplantation in selected cases.
IIb C
The recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and
the American Heart Association and are based on paediatric data only (class, level of evidence). The complete list of references on the above subtopic can be found in ref. 29.
Recommendations on PH therapy, specifically in neonatal chronic lung disease and PPHN,27 and PAH associated with congenital heart disease,26 and the recommendations on
acute PH in the intensive care unit,28 are outlined in the according subtopic articles of this expert consensus statement.
AVT, acute vasodilator testing; CCB, calcium channel blocker; COR, class of recommendation; HPAH, hereditary pulmonary hypertension; iNO, inhaled nitric oxide; IPAH, idiopathic
pulmonary arterial hypertension; LOE, level of evidence; LPA, left pulmonary artery; LV, left ventricle; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PH,
pulmonary hypertension; PPHN, persistent pulmonary hypertension of the newborn; PPHVD, paediatric pulmonary hypertensive vascular disease; RCT, randomised controlled trial;
RV, right ventricle.
Hansmann G et al. Heart 2016;102:ii86–ii100. doi:10.1136/heartjnl-2015-309132 ii93
Pulmonary vascular disease
 on 16 A











Germany; on 4 October 2014 in Weimar, Germany; on 21 May
2015 in Prague, Czech Republic; and on 6 June 2015 in
Weimar, Germany. Of the 144 graded recommendations, 65
were class (COR) I, 72 were class II (39 COR IIa, 33 COR IIb);
and 7 determined as class III (COR III, no benefit or harm).
Three recommendations were LOE A, 41 were LOE B and the
majority, that is, 100, were stratified as LOE C, due to the lack
of randomized controlled studies.
Figure 1 Diagnostic algorithm for a child or adolescent with suspected pulmonary hypertension. BPD, bronchopulmonary dysplasia; CLD, chronic
lung disease; CHD, congenital heart disease; CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest X-ray; HPAH, hereditary
pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; PCH, pulmonary capillary haemangiomatosis; PH, pulmonary
hypertension; PVOD, pulmonary veno-occlusive disease; VQ, ventricular-perfusion.
Figure 2 Determinants of risk in paediatric pulmonary hypertensive vascular disease. The variables listed distinguish between lower and higher
risk. The intermediate risk group is broad and not specifically defined. Overall, these determinants have only level of evidence C due to sparse or
lack of paediatric data. Healthcare providers may include here PVR/SVR ratio, the 6 min walk distance and the max. oxygen consumption (VO2 max.)
obtained during cardiopulmonary exercise testing as risk variables; however, it is unclear where exactly the cut-off values should be set. One must
also note that most of these variables have been validated mostly for IPAH and the cut-off levels used above may not necessarily apply to other
forms of PAH. Furthermore, the use of approved therapies and their influence on the variables should be considered in the evaluation of the risk.
BNP, brain natriuretic peptide; CI, cardiac index (syn. Qs); IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure,
mRAP, mean right atrial pressure; NT-proBNP, N terminal pro BNP; PVRi, pulmonary vascular resistance index; RA, right atrium; RV, right ventricle;
SVRi, systemic vascular resistance index; WHO, World Health Organisation. Modified from McLaughlin and McGoon.31
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Figure 3 Algorithm for management of patients with congenital heart disease associated with PAH/PPVD and congenital shunt lesions. The
indication for invasive diagnostics and eligibility for surgery/operability by comprehensive right and left heart catheterisation includes basic
evaluation and AVT, the latter especially in the grey zone of forecast uncertainty. Modified from: Lopes AA and Barst R and the PVRI PAH-CHD
taskforce (PVRI website; published on 26 September 2013). ASD, atrial septal defect; AVT, acute vasodilative testing; CHD, congenital heart disease;
PDA, patent ductus arteriosus; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; pre OP, preoperatively; PVR, pulmonary vascular
resistance; PVRI, pulmonary vascular resistance index; Qp, pulmonary blood flow; Qs, systemic blood flow; SVR, systemic vascular resistance; WU,
Wood units; VSD, ventricular septal defect PAH, pulmonary arterial hypertension.
Figure 4 Treatment algorithm for paediatric pulmonary arterial hypertension. This algorithm applies to IPAH HPAH (FPAH). Solid clinical data on
the therapy of other forms of PH is limited. The ‘intermediate’ risk group is broad and not specifically defined (see figure 1). Healthcare providers
may consider upfront, early or rapid sequence-targeted PAH therapy in ‘intermediate’ risk group (between ‘lower risk’ and ‘higher risk’ in figure 1:
‘Determinants of risk’). Use of all agents is considered off-label in children aside from sildenafil and bosentan (>1-year-old) in Europe. Sildenafil
dosing recommendations should follow EMA-approved dosing for children. Bosentan received the following dual grading: COR I, LOE B for children
with PAH and Eisenmenger syndrome, and COR IIa, LOE C for children with PAH without Eisenmenger syndrome. CCB, calcium channel blocker;
COR, class of recommendation; ERA, endothelin receptor antagonist; EMA, European Medicines Agency; HPAH, hereditary pulmonary arterial
hypertension; inh., inhalation; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; LOE, level of evidence; PDE-5i, phosphodiesterase 5
inhibitor; PH, pulmonary hypertension;; PAH, pulmonary arterial hypertension; SC, subcutaneous. Modified and expanded from Ivy et al.19
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Each manuscript of the multipaper expert consensus statement
has been peer reviewed by at least two anonymous external
experts according the journal’s standardised review process for
original articles and—in addition—by two anonymous experts
selected by the International Society of Heart and Lung
Transplantation (ISHLT) scientific board.
Endorsement process (ISHLT, DGPK)
The ISHLT was actively involved in the peer review process as
outlined above and endorsed the first five manuscripts on 3
September 2015 and the final five manuscripts on February 9,
2016. The DGPK, that is, the society for paediatric and con-
genital cardiology in Austria, Germany and Switzerland,
endorsed the multipaper expert consensus statement on January
7, 2015 (box 2).
Summary of graded recommendations (COR, LOE) by clinical
topic
See tables 3–11 and figures 1–5 for summary of graded
recommendations.
Limitations of the multipaper expert consensus statement
on paediatric PH
We acknowledge that most LOE of our recommendations on
paediatric PH, are B or C, since only very few randomised con-
trolled trials have been conducted so far due the heterogeneity
of what is still considered a rare—but underdiagnosed—disease
in the so-called developed world. Thus, we called this special
issue ‘Expert Consensus Statement’ rather than ‘Guidelines’. We
Figure 5 Treatment algorithm for combination therapy in PAH (evidenced-based only for adults with PAH, ie, group 1 PH). Bosentan received
the following dual grading: COR I, LOE B for children with PAH and Eisenmenger syndrome, and COR IIa, LOE C for children with PAH without
Eisenmenger syndrome. The ‘intermediate’ risk group is broad and not specifically defined (see figure 1). (a) Some WHO-FC III patients may be
considered high risk (see table 1). (b) In adult PAH, initial combination with ambrisentan plus tadalafil has been shown to be superior to initial
monotherapy with ambrisentan or tadalafil in delaying clinical failure. (c) Intravenous epoprostenol should be prioritised as it has reduced the
3 months rate for mortality in high-risk adult PAH patients also as monotherapy. (d) Consider also balloon atrial septostomy. Modified from Galie
et al.30 CCB, calcium channel blockers; COR, class of recommendation; DPAH, drug-induced PAH; HPAH, heritable PAH; IPAH, idiopathic PAH; i.v.,
intravenous; LOE, level of evidence (according to European Society of Cardiology and American Heart Association). PAH, pulmonary arterial
hypertension; PCA, prostacyclin analogues; WHO-FC, WHO functional class.
Box 3 Challenges and future directions of the European
Paediatric Pulmonary Vascular Disease Network
▸ Identification of valid treatment goals in paediatric PAH.6 32–35
▸ Regulatory requirements, patient recruitment and retention,
clinical trial endpoints for paediatric PAH trials.33 34
▸ Need to conduct multicentre studies and establish new
registries for paediatric pulmonary hypertension.14 34
▸ Initiation of a prospective multicentre study on early
combination therapy in paediatric including a comparative
group (early combined dual or triple combination, rapid
sequence of two agents).
▸ When and how to perform a Potts shunt procedure36
(surgery, intervention?) for advanced PAH and how to
combine this pressure-unloading shunt with combination
pharmacotherapy?
▸ Initiation of investigator-initiated pilot and/or
industry-sponsored phase 2/3 studies on the safety and
efficacy of new compounds recently published/approved
for adult PAH (macitentan, riociguat, selexipag,
treprostinil).29
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do strongly feel—however—that the previous PH documents
provided by adult cardiology or respiratory societies or the
WSPH, while improved, do not reflect to a satisfactory extent
the specific complexity of paediatric PHVD and hence devel-
oped this consensus statement (box 3).
CONCLUSIONS
This multipaper expert consensus statement of the European
Paediatric PVD Network provides a specific, comprehensive,
detailed but practical framework for the optimal clinical care for
children with PH/PHVD. Additional patient registries and pro-
spective, controlled and randomised studies on the diagnosis
and treatment of PH in children are urgently needed to move
on from frequently experience-based towards mostly evidence-
based recommendations.
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